488 related articles for article (PubMed ID: 7604807)
21. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia.
Milani M; Cimminiello C; Merlo B; Lorena M; Arpaia G; Bonfardeci G
Am J Cardiol; 1995 Jul; 76(2):51A-53A. PubMed ID: 7604798
[TBL] [Abstract][Full Text] [Related]
22. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
[TBL] [Abstract][Full Text] [Related]
23. Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate.
Greten H; Beil FU; Schneider J; Weisweiler P; Armstrong VW; Keller C; Klör HU; von Hodenberg E; Weidinger G; Eskötter H
Am J Med; 1994 Jun; 96(6A):55S-63S. PubMed ID: 8017468
[TBL] [Abstract][Full Text] [Related]
24. Effects of fluvastatin on human biliary lipids.
Tazuma S; Ohya T; Mizuno T; Takizawa I; Kunita T; Takata K; Hayashi K; Hino F; Tokumo H; Watanabe T
Am J Cardiol; 1995 Jul; 76(2):110A-113A. PubMed ID: 7604783
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of the combination of fluvastatin and gemfibrozil.
Spence JD; Munoz CE; Hendricks L; Latchinian L; Khouri HE
Am J Cardiol; 1995 Jul; 76(2):80A-83A. PubMed ID: 7604806
[TBL] [Abstract][Full Text] [Related]
26. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients.
Sprecher DL; Abrams J; Allen JW; Keane WF; Chrysant SG; Ginsberg H; Fischer JJ; Johnson BF; Theroux P; Jokubaitis L
Ann Intern Med; 1994 Apr; 120(7):537-43. PubMed ID: 8093139
[TBL] [Abstract][Full Text] [Related]
27. Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency.
Lintott CJ; Scott RS; Bremer JM; Shand BI
Am J Cardiol; 1995 Jul; 76(2):97A-101A. PubMed ID: 7604809
[TBL] [Abstract][Full Text] [Related]
28. Outcome monitoring of fluvastatin in a Department of Veterans Affairs lipid clinic.
Kellick KA; Burns K; McAndrew E; Haberl E; Hook N; Ellis A
Am J Cardiol; 1995 Jul; 76(2):62A-64A. PubMed ID: 7604801
[TBL] [Abstract][Full Text] [Related]
29. Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin.
Smit JW; Wijnne HJ; Schobben F; Sitsen A; de Bruin TW; Erkelens DW
Am J Cardiol; 1995 Jul; 76(2):89A-96A. PubMed ID: 7604808
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels.
Spieker LE; Noll G; Hannak M; Lüscher TF
J Cardiovasc Pharmacol; 2000 Mar; 35(3):361-5. PubMed ID: 10710119
[TBL] [Abstract][Full Text] [Related]
31. Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin.
Herd JA; West MS; Ballantyne C; Farmer J; Gotto AM
Am J Cardiol; 1994 May; 73(14):42D-49D. PubMed ID: 8198024
[TBL] [Abstract][Full Text] [Related]
32. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease.
Eichstädt HW; Eskötter H; Hoffman I; Amthauer HW; Weidinger G
Am J Cardiol; 1995 Jul; 76(2):122A-125A. PubMed ID: 7604786
[TBL] [Abstract][Full Text] [Related]
33. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
34. Fluvastatin with and without niacin for hypercholesterolemia.
Jacobson TA; Chin MM; Fromell GJ; Jokubaitis LA; Amorosa LF
Am J Cardiol; 1994 Jul; 74(2):149-54. PubMed ID: 8023779
[TBL] [Abstract][Full Text] [Related]
35. Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine.
Hagen E; Istad H; Ose L; Bodd E; Eriksen HM; Selvig V; Bard JM; Fruchart JC; Borge M; Wolf MC
Eur J Clin Pharmacol; 1994; 46(5):445-9. PubMed ID: 7957541
[TBL] [Abstract][Full Text] [Related]
36. Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia.
Isaacsohn JL; LaSalle J; Chao G; Gonasun L
Clin Ther; 2003 Mar; 25(3):904-18. PubMed ID: 12852707
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin in hyperlipidemic patients treated with probucol.
Sasaki S; Nakagawa M; Nakata T; Endo N; Miyao K; Kitamura K; Fukuyama M; Kitani T; Yamada C
Cardiology; 1997; 88(2):160-5. PubMed ID: 9096917
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
39. [Fluvastatin in the treatment of hyperlipoproteinemia, initial experience].
Ceska R
Vnitr Lek; 1996 Aug; 42(8):533-6. PubMed ID: 8967021
[TBL] [Abstract][Full Text] [Related]
40. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.
Arch Intern Med; 1993 Jun; 153(11):1321-9. PubMed ID: 8507122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
